PMA device
Hymovis
Fidia Farmaceutici · Acid, Hyaluronic, Intraarticular (MOZ, Class III) · First FDA decision Aug 28, 2015, newest Aug 28, 2015Knee osteoarthritis
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
7
Naming "Hymovis"
MAUDE reports
26
Brand "Hymovis", since 2015
PubMed studies
21
Mentioning "Hymovis"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Hymovis
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- HYMOVISPMA
P150010 · Decided Aug 28, 2015 · 184 days after receipt
Device type: Acid, hyaluronic, intraarticular (MOZ) · Orthopedic Surgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Hymovis", any status and sponsor, newest update first.
- Comparative Study of Two Hyaluronic Acid Formulation in the Management of Knee OsteoarthritisPivotal-lookingCompleted
Fidia Farmaceutici s.p.a.Not on our public-company list
NCT06528600 · 350 participants · Start Sep 16, 2020 · Primary completion Mar 15, 2024
Device: Hymovis ONE; Monovisc · For: Osteoarthritis, Knee
Sites: Brescia, Italy; Esine, Italy; Caserta, Italy · 19 sites in all
Concordia Hospital RomeAcademic, hospital or other
NCT06043544 · 80 participants · Start May 2, 2021 · Primary completion Nov 10, 2021
Device: Hyaluronic Acid 24 MG in 3 mL Prefilled Syringe · For: Glenohumeral Osteoarthritis
Sites: Rome, Italy
Fidia Farmaceutici s.p.a.Not on our public-company list
NCT04661111 · 31 participants · Start Jun 13, 2016 · Primary completion Sep 28, 2017
Device: Hymovis® ONE (32 mg/4 ml) · For: Knee Osteoarthritis
Sites: Roma, Italy
4 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Hymovis", and for the whole product code for context.
This brand
26 reports: 0 malfunction, 26 injury, 0 death
Whole product code MOZ
4,975 reports: 669 malfunction, 3,945 injury, 278 death
Newest reports for this brand
- HYMOVISInjury
9610200-2026-00002 · Received Jul 7, 2026 · Event dated Jun 11, 2026
Device type: Acid, Hyaluronic, Intraarticular (MOZ)
Device problem as coded: Appropriate Device Problem Term/Code Not Available
Patient problem as coded: Arthralgia; Swelling/ Edema
- HYMOVISInjury
3009107511-2025-00001 · Received Jun 27, 2025
Device type: Acid, Hyaluronic, Intraarticular (MOZ)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Arthritis; Fever; Arthralgia; Ambulation or Postural Difficulties; Administration Site Reaction; Administration Site Swelling
- HYMOVISInjury
3009107511-2025-00002 · Received Jun 27, 2025 · Event dated Apr 14, 2025
Device type: Acid, Hyaluronic, Intraarticular (MOZ)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Chest Pain; Dyspnea; Dizziness; Arthralgia; Joint effusion
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Hymovis"[tiab]. The summary above synthesizes these.
- The relationship between synovial inflammation, structural pathology, and pain in post-traumatic osteoarthritis: differential effect of stem cell and hyaluronan treatment.
Shu CC, Zaki S, Ravi V, et al. · Arthritis Res Ther · 2020Research Support, Non-U.S. Gov't
- Single-injection hyaluronic acid treatment demonstrates non-inferiority in the relief of symptomatic knee osteoarthritis: A randomized double-blind, multi-center controlled study.
Ruosi C, Longo UG, Giordan N, et al. · Osteoarthr Cartil Open · 2026
- Efficacy of a Single Intra-Articular HYMOVIS ONE Injection for Managing Symptomatic Hip Osteoarthritis: A 12-Month Follow-Up Retrospective Analysis of the ANTIAGE Register Data.
Migliore A, Frediani B, Gigliucci G, et al. · Orthop Res Rev · 2020
- Hyaluronan derivative HYMOVIS® increases cartilage volume and type ii collagen turnover in osteoarhritic knee: data from MOKHA study.
Henrotin Y, Bannuru R, Malaise M, et al. · BMC Musculoskelet Disord · 2019Clinical Trial, Multicenter Study
- A multi-centre, open label, long-term follow-up study to evaluate the benefits of a new viscoelastic hydrogel (Hymovis®) in the treatment of knee osteoarthritis.
Benazzo F, Perticarini L, Padolino A, et al. · Eur Rev Med Pharmacol Sci · 2016Clinical Trial, Phase III, Multicenter Study
- Inflammatory and Noninflammatory Synovial Fluids Exhibit New and Distinct Tribological Endotypes.
Feeney E, Galesso D, Secchieri C, et al. · J Biomech Eng · 2020Research Support, U.S. Gov't, Non-P.H.S.
- Treatment Efficacy with a Novel Hyaluronic Acid-Based Hydrogel for Osteoarthritis of the Knee.
Russu OM, Pop TS, Feier AM, et al. · J Pers Med · 2021
- Intra-articular Hymovis injection for managing hip OA in active sportsmen. A 24-month observational retrospective clinical investigation.
Rando G, Pastorino R · J Clin Orthop Trauma · 2021
- Hymovis MO.RE. in the treatment of knee and ankle chondropathy in elite athletes: preliminary results of the CHAMPS (Cohort study about HYADD4-G Administration for Pain relief on Soccer players) prospective clinical study.
Perticarini L, Baldari A, Bruzzone M, et al. · Eur Rev Med Pharmacol Sci · 2021Multicenter Study
- The efficacy of intra-articular HYADD4-G injection in the treatment of femoroacetabular impingement: results at one year follow up.
Ometti M, Schipani D, Conte P, et al. · J Drug Assess · 2020
- New Viscoelastic Hydrogel Hymovis MO.RE. Single Intra-articular Injection for the Treatment of Knee Osteoarthritis in Sportsmen: Safety and Efficacy Study Results.
Bernetti A, Agostini F, Alviti F, et al. · Front Pharmacol · 2021
- Intra-articular glenohumeral injections of HYADD®4-G for the treatment of painful shoulder osteoarthritis: a prospective multicenter, open-label trial.
Porcellini G, Merolla G, Giordan N, et al. · Joints · 2015
Other devices of this type
Also filed under product code MOZ.
- EUFLEXXA (1% Sodium Hyaluronate)Ferring Pharmaceuticals, Inc. · PMA 2017
- Gel-One(R)Seikagaku Corp. · PMA 2016
- Supartz FxSeikagaku Corp. · PMA 2016
- SupartzSeikagaku Corp. · PMA 2015
- Orthovisc High Molecular Weight HyaluronanAnika Therapeutics, Inc. · PMA 2011
- DurolaneBioventus, LLC · PMA 2020
- MonoviscAnika Therapeutics, Inc. · PMA 2020
- HyalganFidia Farmaceutici S.P.A. · PMA 2008
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.